Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s McClellan Touts Scientific Analysis As Part Of Ephedra Ban

This article was originally published in The Tan Sheet

Executive Summary

FDA Commissioner Mark McClellan, MD/PhD, said the "framework" for the outright ban of ephedra will be based on substantive scientific evidence as the agency prepares to publish the reg
Advertisement

Related Content

NTP Board Shows Support For More Dietary Supplement Evaluations
CFSAN Examines AER Reporting Following Bitter Orange Miscalculation
A Bitter Pill? Researchers Challenge Citrus Aurantium Safety, Efficacy
Consumer Reports Article Highlights “Dangerous” Supplements
Chattem Shipments Of Dexatrim With Bitter Orange To Halt In May
Bitter Orange Safety Concerns Raised By Sen. Schumer, Rep. Waxman
Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
Aristolochia Renal Disease Link Reported In Two U.S. Cases

Topics

Advertisement
UsernamePublicRestriction

Register

PS096396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel